ASCO 2024: Camrelizumab plus Apatinib for Previously Treated

advanced adrenocortical carcinoma, camrelizumab, Apatinib, Camrelizumab plus Apatinib.

Related Keywords

Chicago , Illinois , United States , Sichuan , Gansu , China , Toronto , Ontario , Canada , American , Zhigong Wei , Society Of Urologic Oncology , Twitter , American Society Of Clinical Oncology , University Of Toronto , Sichuan University , Department Of Biotherapy , Cancer Center , Clinical Oncology , Annual Meeting , West China Hospital , Rashid Sayyid , Urologic Oncology , Clinical Fellow , Advanced Adrenocortical ,